General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Merck(MODEST), Boehringer Ingelheim(SIGNIFICANT), Novo Nordisk Inc.(SIGNIFICANT), Lilly US(MODEST), Pfizer Inc(NONE), GlaxoSmithKline(SIGNIFICANT), Bayer(SIGNIFICANT) RESEARCH/RESEARCH GRANTS: Boehringer Ingelheim(SIGNIFICANT), Novo Nordisk Inc.(SIGNIFICANT), Merck(MODEST), AstraZeneca(SIGNIFICANT), Esperion(MODEST), Lilly USA(SIGNIFICANT) OTHER FINANCIAL BENEFIT: Abbott Laboratories(SIGNIFICANT)

View Full Disclosure